Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Humacyte is a commercial-stage biotechnology company developing bioengineered human tissues. Its primary product, Symvess (acellular tissue engineered vessel), received FDA approval in December 2024 for vascular trauma and commenced commercial sales in the U.S. in early 2025. The company is advancing Phase 3 trials for AV access in hemodialysis and PAD.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $495 | $517 |
| Net Loss | $(17,619) | $39,139 (Income) |
| Operating Loss | $(28,935) | $(23,184) |
| Cash and Cash Equivalents | $48,539 | $95,290 (Beginning Q1 2025) |
| Working Capital | $47,410 | $49,423 (Dec 31, 2025) |
| Long-Term Debt (Carrying Value) | $35,871 | $35,444 |
| Net Cash Used in Operating Activities | $(25,104) | $(28,601) |
Note: Q1 2025 Net Income was driven by significant non-cash gains from fair value adjustments of liabilities, not operational profitability.
Material Changes vs. Prior Period
- Revenue Composition: Product revenue increased to $0.5 million (from $0.1 million in Q1 2025) due to Symvess commercialization. However, contract revenue dropped significantly to $2,000 (from $370,000), resulting in a slight overall revenue decrease.
- Cost of Goods Sold (COGS): Increased to $2.0 million from $0.1 million. This includes a $1.6 million inventory reserve for obsolescence and unused production capacity costs.
- Operating Expenses: R&D expenses rose 26% to $19.5 million, driven by a $4.3 million increase in materials and supplies for non-commercial manufacturing runs. G&A expenses remained relatively flat at $7.9 million.
- Non-Cash Gains: Total other income decreased by $51.0 million to $11.3 million. This decline is primarily due to reduced non-cash gains from the remeasurement of the Contingent Earnout Liability ($4.7 million gain vs. $49.7 million in prior year) and derivative liabilities.
- Capital Structure: The company completed a Registered Direct Offering in March 2026, issuing 25 million shares at $0.80 for net proceeds of $18.3 million. It also raised $4.6 million via its ATM facility.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern. With $48.5 million in cash, the company estimates it cannot fund operations beyond one year without additional capital or significant commercial sales growth.
- Cost Reduction Plan: In May 2026 (subsequent to period end), the company implemented a workforce reduction of approximately 45 employees and deferred new hires. Estimated one-time charges are $0.8 million, with projected net savings of $14.3 million for the remainder of 2026.
- Strategic Shift: In April 2026, the company amended its distribution agreement with Fresenius Medical Care to regain worldwide commercialization rights for its products, paying low-single-digit royalties on ex-U.S. sales.
- Regulatory & Clinical: The company plans to file a supplemental BLA for the AV access indication in the second half of 2026 pending positive interim results from the V012 Phase 3 trial. An MAA was filed in Israel in March 2026.
- Listing Risk: The company received a Nasdaq delisting notice in May 2026 due to the stock price closing below $1.00 for 30 consecutive days. It has 180 days to regain compliance.
- Legal Proceedings: A securities class action lawsuit regarding product safety and manufacturing deficiencies remains active, with discovery expected to commence shortly. Several derivative actions are stayed pending the resolution of the class action.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and current burn rate of ~$25M per quarter.
- Inventory Valuation: Assess the $1.6 million inventory reserve and the remaining $10.5 million allowance for obsolescence against actual Symvess sales velocity.
- Nasdaq Compliance: Monitor the stock price to determine if the company will regain compliance with the $1.00 minimum bid price requirement by November 2026.
- Debt Covenants: Review the terms of the $40M Term Loan Facility (11.5% interest) and the conditions required to access the remaining $37.5M in tranches.
- Legal Exposure: Track the status of the securities class action lawsuit and potential impact on the company's reputation and financials.